1.Clinical Outcome after Everolimus-Eluting Stent Implantation for Small Vessel Coronary Artery Disease: XIENCE Asia Small Vessel Study
Doo Sun SIM ; Dae Young HYUN ; Young Joon HONG ; Ju Han KIM ; Youngkeun AHN ; Myung Ho JEONG ; Sang Rok LEE ; Jei Keon CHAE ; Keun Ho PARK ; Young Youp KOH ; Kyeong Ho YUN ; Seok Kyu OH ; Seung Jae JOO ; Sun Ho HWANG ; Jong Pil PARK ; Jay Young RHEW ; Su Hyun KIM ; Jang Hyun CHO ; Seung Uk LEE ; Dong Goo KANG
Chonnam Medical Journal 2024;60(1):78-86
There are limited data on outcomes after implantation of everolimus-eluting stents (EES) in East Asian patients with small vessel coronary lesions. A total of 1,600 patients treated with XIENCE EES (Abbott Vascular, CA, USA) were divided into the small vessel group treated with one ≤2.5 mm stent (n=119) and the non-small vessel group treated with one ≥2.75 mm stent (n=933). The primary end point was a patient-oriented composite outcome (POCO), a composite of all-cause death, myocardial infarction (MI), and any repeat revascularization at 12 months. The key secondary end point was a device-oriented composite outcome (DOCO), a composite of cardiovascular death, target-vessel MI, and target lesion revascularization at 12 months. The small vessel group was more often female, hypertensive, less likely to present with ST-elevation MI, and more often treated for the left circumflex artery, whereas the non-small vessel group more often had type B2/C lesions, underwent intravascular ultrasound, and received unfractionated heparin. In the propensity matched cohort, the mean stent diameter was 2.5±0.0 mm and 3.1±0.4 mm in the small and non-small vessel groups, respectively. Propensity-adjusted POCO at 12 months was 6.0% in the small vessel group and 4.3% in the non-small vessel group (p=0.558). There was no significant difference in DOCO at 12 months (small vessel group: 4.3% and non-small vessel group: 1.7%, p=0.270).Outcomes of XIENCE EES for small vessel disease were comparable to those for non-small vessel disease at 12-month clinical follow-up in real-world Korean patients.
2.Impact of Crohn’s Disease on the Survival of Patients with Small-Bowel Adenocarcinoma in Korea: A Bicenter Cohort Study
Kyuwon KIM ; Kookhwan CHOI ; Sung Wook HWANG ; Jong Pil IM ; Byong Duk YE ; Joo Sung KIM ; Kyu Joo PARK ; Suk-Kyun YANG ; Seong-Joon KOH ; Sang Hyoung PARK ;
Gut and Liver 2023;17(4):581-590
Background/Aims:
Owing to the low prevalence of small-bowel adenocarcinoma (SBA), data on the impact of Crohn’s disease (CD) on the survival of patients with SBA are lacking. Therefore, we investigated this issue in this study.
Methods:
In this bicenter cohort study, patients with histologically confirmed SBA were retrospectively enrolled and classified into two groups: sporadic SBA and CD-associated SBA. Patients with duodenal SBA were excluded. Overall survival, disease-free survival, and factors associated with survival were analyzed.
Results:
Of 128 patients with SBA, 115 had sporadic SBA and 13 had CD-associated SBA. Ileal involvement and poorly differentiated tumors were more common in the CD-associated SBA group than in the sporadic SBA group (ileal involvement, 53.8% vs 22.6%; poor differentiation, 46.2% vs 14.8%; both p<0.05). In survival analysis, overall survival showed no statistical difference between the sporadic SBA and CD-associated SBA groups (p=0.370). However, when stratified by stage, the adjusted overall survival of the CD-associated SBA group was lower in patients with an advanced disease stage (p=0.029). Disease-free survival showed the same tendency, albeit without clinical significance (p=0.097). CD (hazard ratio [HR], 2.308; p=0.047), older age (≥65 yr) at SBA diagnosis (HR, 2.766; p=0.001), and stage III/IV disease (HR, 3.151; p<0.001) were factors associated with mortality.
Conclusions
The overall survival of patients with CD-associated SBA did not differ from that of patients with sporadic SBA. However, as CD is an independent risk factor for mortality, vigilant surveillance in high-risk patients may be crucial.
3.Medical Issues and Opinions of Obstetrics Regarding Abortion Law Amendment
Anna CHOI ; Yong Won PARK ; Sei Kwang KIM ; Seung Cheol KIM ; Pil Ryang LEE ; Kyoung Joo HWANG ; Jae Kwan LEE ; Kyung SEO ; Young Ju KIM ; Dong Hyun CHA ; Sunghun NA ; Dong Suk KIM ; Young Kyu LEE ; Youngseok WON ; Jae Yoo KIM ; Jaeyean KIM ; Jinhak KIM ; Woong JU ; Mi-Kyung KIM ; Jeong Yoel PARK
Journal of the Korean Society of Maternal and Child Health 2020;24(1):9-17
There have been ongoing social discussions on revision of the abortion law since the Constitutional Court ruled it nonconformity to the constitution on April 11, 2019. Thus, Korean Society of Obstetrics and Gynecology, Korean Society of Maternal Fetal Medicine, Korean College of Obstetricians and Gynecologists, and Korean Association of Obstetricians and Gynecologists organized 'special committee for abortion law' to support social discussion on the revision of the abortion law, and they prepared official opinions of obstetrics for medical issues including doctors' right to refuse abortion. In the future, the committee will continue to adapt to changes of medical environment especially after the revision of the abortion law by collecting its members' feedbacks.
4.Medical Issues and Opinions of Obstetrics Regarding Abortion Law Amendment
Anna CHOI ; Yong Won PARK ; Sei Kwang KIM ; Seung Cheol KIM ; Pil Ryang LEE ; Kyoung Joo HWANG ; Jae Kwan LEE ; Kyung SEO ; Young Ju KIM ; Dong Hyun CHA ; Sunghun NA ; Dong Suk KIM ; Young Kyu LEE ; Youngseok WON ; Jae Yoo KIM ; Jaeyean KIM ; Jinhak KIM ; Woong JU ; Mi-Kyung KIM ; Jeong Yoel PARK
Journal of the Korean Society of Maternal and Child Health 2020;24(1):9-17
There have been ongoing social discussions on revision of the abortion law since the Constitutional Court ruled it nonconformity to the constitution on April 11, 2019. Thus, Korean Society of Obstetrics and Gynecology, Korean Society of Maternal Fetal Medicine, Korean College of Obstetricians and Gynecologists, and Korean Association of Obstetricians and Gynecologists organized 'special committee for abortion law' to support social discussion on the revision of the abortion law, and they prepared official opinions of obstetrics for medical issues including doctors' right to refuse abortion. In the future, the committee will continue to adapt to changes of medical environment especially after the revision of the abortion law by collecting its members' feedbacks.
5.Korean Clinical Practice Guidelines for Aneurysmal Subarachnoid Hemorrhage
Won Sang CHO ; Jeong Eun KIM ; Sukh Que PARK ; Jun Kyeung KO ; Dae Won KIM ; Jung Cheol PARK ; Je Young YEON ; Seung Young CHUNG ; Joonho CHUNG ; Sung Pil JOO ; Gyojun HWANG ; Deog Young KIM ; Won Hyuk CHANG ; Kyu Sun CHOI ; Sung Ho LEE ; Seung Hun SHEEN ; Hyun Seung KANG ; Byung Moon KIM ; Hee Joon BAE ; Chang Wan OH ; Hyeon Seon PARK ; ; ; ;
Journal of Korean Neurosurgical Society 2018;61(2):127-166
Despite advancements in treating ruptured cerebral aneurysms, an aneurysmal subarachnoid hemorrhage (aSAH) is still a grave cerebrovascular disease associated with a high rate of morbidity and mortality. Based on the literature published to date, worldwide academic and governmental committees have developed clinical practice guidelines (CPGs) to propose standards for disease management in order to achieve the best treatment outcomes for aSAHs. In 2013, the Korean Society of Cerebrovascular Surgeons issued a Korean version of the CPGs for aSAHs. The group researched all articles and major foreign CPGs published in English until December 2015 using several search engines. Based on these articles, levels of evidence and grades of recommendations were determined by our society as well as by other related Quality Control Committees from neurointervention, neurology and rehabilitation medicine. The Korean version of the CPGs for aSAHs includes risk factors, diagnosis, initial management, medical and surgical management to prevent rebleeding, management of delayed cerebral ischemia and vasospasm, treatment of hydrocephalus, treatment of medical complications and early rehabilitation. The CPGs are not the absolute standard but are the present reference as the evidence is still incomplete, each environment of clinical practice is different, and there is a high probability of variation in the current recommendations. The CPGs will be useful in the fields of clinical practice and research.
Aneurysm
;
Brain Ischemia
;
Cerebrovascular Disorders
;
Diagnosis
;
Disease Management
;
Hydrocephalus
;
Intracranial Aneurysm
;
Mortality
;
Neurology
;
Quality Control
;
Rehabilitation
;
Risk Factors
;
Search Engine
;
Subarachnoid Hemorrhage
;
Surgeons
6.Metronidazole-induced encephalopathy in a patient with Crohn's disease.
Jihye KIM ; Jaeyoung CHUN ; Jae Yong PARK ; Seung Wook HONG ; Joo Young LEE ; Jin Woo KANG ; Seongjun HWANG ; Sang Bae KO ; Jong Pil IM ; Joo Sung KIM
Intestinal Research 2017;15(1):124-129
Metronidazole is a widely used antibiotic for the treatment of anaerobic bacterial infections. Metronidazole-induced encephalopathy (MIEP) is a rare but potentially reversible disease. The mechanism of MIEP remains unclear, and differences in the neurotoxic effects of oral versus intravenous (IV) metronidazole administration have not yet been determined. We report the case of a Crohn's disease (CD) patient who experienced encephalopathy immediately after a single IV dose of metronidazole following long-term exposure to the oral form of the drug. The 64-year-old man with intractable CD experienced a sudden change in mental status, aphasia, and muscle weakness after IV administration of metronidazole. He had previously taken metronidazole orally for 13 years and received intermittent IV metronidazole treatments for CD exacerbation. Brain magnetic resonance imaging (MRI) showed high-intensity signals in the bilateral medial thalamus and the midbrain and pontine tegmentum on fluid-attenuated inversion recovery images. After discontinuation of metronidazole, the high-intensity brain MRI signals resolved and the patient's mental status dramatically improved; however, the patient exhibited mild cognitive dysfunction 2 months after the onset of encephalopathy.
Aphasia
;
Bacterial Infections
;
Brain
;
Brain Diseases*
;
Brain Diseases, Metabolic
;
Crohn Disease*
;
Drug-Related Side Effects and Adverse Reactions
;
Humans
;
Magnetic Resonance Imaging
;
Mesencephalon
;
Metronidazole
;
Middle Aged
;
Muscle Weakness
;
Pontine Tegmentum
;
Thalamus
7.Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease.
Joo Hyun LIM ; Sang Gyun KIM ; Ji Hyun SONG ; Jae Jin HWANG ; Dong Ho LEE ; Jae Pil HAN ; Su Jin HONG ; Ji Hyun KIM ; Seong Woo JEON ; Gwang Ha KIM ; Ki Nam SHIM ; Woon Geon SHIN ; Tae Ho KIM ; Sun Moon KIM ; Il Kwon CHUNG ; Hyun Soo KIM ; Heung Up KIM ; Joongyub LEE ; Jae Gyu KIM
Gut and Liver 2017;11(2):226-231
BACKGROUND/AIMS: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. METHODS: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed. RESULTS: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/gastroduodenal ulcer, 68.8%, p=0.655). CONCLUSIONS: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.
Amoxicillin
;
Clarithromycin
;
Compliance
;
Follow-Up Studies
;
Helicobacter pylori*
;
Helicobacter*
;
Humans
;
Levofloxacin
;
Peptic Ulcer*
;
Ulcer
8.Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy.
Hae Lim LEE ; Si Hyun BAE ; Bohyun JANG ; Seawon HWANG ; Hyun YANG ; Hee Chul NAM ; Pil Soo SUNG ; Sung Won LEE ; Jeong Won JANG ; Jong Young CHOI ; Nam Ik HAN ; Byung Joo SONG ; Jong Wook LEE ; Seung Kew YOON
Gut and Liver 2017;11(6):870-877
BACKGROUND/AIMS: According to the results of several studies, the outcome of hepatitis C virus (HCV) reactivation is not as severe as the outcome of hepatitis B virus reactivation. The aim of this study was to evaluate the effect of pharmacological immunosuppression on HCV reactivation. METHODS: The medical records of patients who underwent systemic chemotherapy, corticosteroid therapy, or other immunosuppressive therapies between January 2008 and March 2015 were reviewed. Subsequently, 202 patients who were seropositive for the anti-HCV antibody were enrolled. Exclusion criteria were: unavailability of data on HCV RNA levels, a history of treatment for chronic hepatitis C, and the presence of liver diseases other than a chronic HCV infection. RESULTS: Among the 120 patients enrolled in this study, hepatitis was present in 46 patients (38%). None of the patients were diagnosed with severe hepatitis. Enhanced replication of HCV was noted in nine (27%) of the 33 patients who had data available on both basal and follow-up HCV RNA loads. Reappearance of the HCV RNA from an undetectable state did not occur after treatment. The cumulative rate of enhanced HCV replication was 23% at 1 year and 30% at 2 years. CONCLUSIONS: Although enhanced HCV replication is relatively common in HCV-infected patients treated with chemotherapy or immunosuppressive therapy, it does not lead to serious sequelae.
Drug Therapy*
;
Follow-Up Studies
;
Hepacivirus*
;
Hepatitis B virus
;
Hepatitis C*
;
Hepatitis C, Chronic
;
Hepatitis*
;
Humans
;
Immunosuppression
;
Liver Diseases
;
Medical Records
;
RNA
9.The Relationship between the Size and the Invasion Depth of Tumors in Head and Neck Cutaneous Squamous Cell Carcinoma.
Sam Yong LEE ; Won Joo HWANG ; Kyung Pil KIM ; Hong Min KIM ; Jae Ha HWANG ; Kwang Seog KIM
Archives of Plastic Surgery 2016;43(6):538-543
BACKGROUND: Cutaneous squamous cell carcinoma (SCC), which occurs in keratinocytes of the epidermis and is the second most common skin cancer, has a more invasive growth pattern and higher potential to metastasize than basal cell carcinoma. Total excision of the primary tumor is the treatment of choice. For clear excision of the tumor, invasion depth is one of the most important factors. This study was conducted to clarify the relationship between the size and the invasion depth of cutaneous SCC. METHODS: Twenty-six cases were collected for this prospective study. Frozen biopsies were examined after complete resection of the tumor, followed by histological confirmation by pathological examination. The major and minor axis lengths of the tumor, the invasion depth, and the level of invasion were measured. Recurrence or metastasis was recorded through regular follow-up. RESULTS: The Pearson correlation coefficient was used for statistical analysis. Significant results were observed for the relationship between the major and minor axis lengths and the invasion depth of the tumor (0.747, 0.773). No cases of recurrence or metastasis were observed. CONCLUSIONS: In head and neck cutaneous SCC, the invasion depth of the tumor is closely related to the major and minor axis lengths of the tumor. Therefore, the invasion depth of the tumor can be estimated by measuring the size of the tumor, and a standard vertical safety margin for head and neck cutaneous SCC can be established, which could be helpful in the development of a preoperative reconstruction plan.
Biopsy
;
Carcinoma, Basal Cell
;
Carcinoma, Squamous Cell*
;
Epidermis
;
Epithelial Cells*
;
Follow-Up Studies
;
Head*
;
Keratinocytes
;
Neck*
;
Neoplasm Metastasis
;
Prospective Studies
;
Recurrence
;
Skin Neoplasms
10.Characteristics and outcomes of endoscopically resected colorectal cancers that arose from sessile serrated adenomas and traditional serrated adenomas.
Ji Yeon SEO ; Seung Ho CHOI ; Jaeyoung CHUN ; Changhyun LEE ; Ji Min CHOI ; Eun Hyo JIN ; Sung Wook HWANG ; Jong Pil IM ; Sang Gyun KIM ; Joo Sung KIM
Intestinal Research 2016;14(3):270-279
BACKGROUND/AIMS: The efficacy and safety of endoscopic resection of colorectal cancer derived from sessile serrated adenomas or traditional serrated adenomas are still unknown. The aims of this study were to verify the characteristics and outcomes of endoscopically resected early colorectal cancers developed from serrated polyps. METHODS: Among patients who received endoscopic resection of early colorectal cancers from 2008 to 2011, cancers with documented pre-existing lesions were included. They were classified as adenoma, sessile serrated adenoma, or traditional serrated adenoma according to the baseline lesions. Clinical characteristics, pathologic diagnosis, and outcomes were reviewed. RESULTS: Overall, 208 colorectal cancers detected from 198 patients were included: 198 with adenoma, five with sessile serrated adenoma, and five with traditional serrated adenoma. The sessile serrated adenoma group had a higher prevalence of high-grade dysplasia (40.0% vs. 25.8%, P<0.001) than the adenoma group. During follow-up, local recurrence did not occur after endoscopic resection of early colorectal cancers developed from serrated polyps. In contrast, two cases of metachronous recurrence were detected within a short follow-up period. CONCLUSIONS: Cautious observation and early endoscopic resection are recommended when colorectal cancer from serrated polyp is suspected. Colorectal cancers from serrated polyp can be treated successfully with endoscopy.
Adenoma*
;
Colonic Polyps
;
Colonoscopy
;
Colorectal Neoplasms*
;
Diagnosis
;
Endoscopy
;
Follow-Up Studies
;
Humans
;
Polyps
;
Prevalence
;
Recurrence

Result Analysis
Print
Save
E-mail